Note 4 - Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2017

Notes Tables

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

			Fair Value Measurements at September 30, 2017
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Balance at September 30,2017
Assets:
Money market funds	$	94,589	$	94,589	$	-	$	-
Total assets	$	94,589	$	94,589	$	-	$	-
Liabilities:
Contingent consideration liability	$	17,500	$	-	$	-	$	17,500
Total liabilities	$	17,500	$	-	$	-	$	17,500

			Fair Value Measurements at December 31, 2016
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Balance at December 31, 2016
Assets:
Money market funds	$	137,340	$	137,340	$	-	$	-
Total assets	$	137,340	$	137,340	$	-	$	-
Liabilities:
Contingent consideration liability	$	14,200	$	-	$	-	$	14,200
Total liabilities	$	14,200	$	-	$	-	$	14,200

Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]

Program	Consideration		Form of Payment at Progenics' Option
AZEDRA	$	8,000	Cash or Progenics common stock
1404		10,000	Cash or Progenics common stock
1095		5,000	Cash or Progenics common stock
	$	23,000

Calendar Year Net Sales Level	Consideration		Form of Payment at Progenics' Option
$30 million	$	5,000	Cash or Progenics common stock
$60 million		5,000	Cash or Progenics common stock
$100 million		10,000	Cash or Progenics common stock
$250 million		20,000	Cash or Progenics common stock
$500 million		30,000	Cash or Progenics common stock
	$	70,000

Fair Value Inputs, Assets and Liabilities, Quantitative Information [Table Text Block]

	Fair Value at
	September 30,
	2017		Valuation Technique	Unobservable Input	Assumption
Contingent Consideration Liability:
AZEDRA commercialization	$	5,400	Probability adjusted discounted	Probability of success			72%
			cash flow model	Period of expected milestone achievement			2018
				Discount rate			10%
1404 commercialization		5,000	Probability adjusted discounted	Probability of success			59%
			cash flow model	Period of expected milestone achievement			2019
				Discount rate			10%
1095 commercialization		400	Probability adjusted discounted	Probability of success			16%
			cash flow model	Period of expected milestone achievement			2024
				Discount rate			10%
Net sales targets		6,700	Monte-Carlo simulation	Probability of success		16%	-	72%
				Discount rate			10%
Total	$	17,500

	Fair Value at
	December 31,
	2016		Valuation Technique	Unobservable Input	Assumption
Contingent Consideration Liability:
AZEDRA commercialization	$	3,800	Probability adjusted discounted	Probability of success		54%
			cash flow model	Period of expected milestone achievement		2018
				Discount rate		10%
1404 commercialization		4,700	Probability adjusted discounted	Probability of success		59%
			cash flow model	Period of expected milestone achievement		2019
				Discount rate		10%
1095 commercialization		400	Probability adjusted discounted	Probability of success		16%
			cash flow model	Period of expected milestone achievement		2024
				Discount rate		10%
Net sales targets		5,300	Monte-Carlo simulation	Probability of success	16%	-	59%
				Discount rate		10%
Total	$	14,200

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Liability - Contingent Consideration
	Fair Value Measurements Using
	Significant Unobservable Inputs
	(Level 3)
	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Balance at beginning of period	$	16,800	$	19,600	$	14,200	$	18,800
Fair value change included in net (loss) income		700		600		3,300		1,400
Balance at end of period	$	17,500	$	20,200	$	17,500	$	20,200
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period	$	700	$	600	$	3,300	$	1,400